HER2/EGFR2, a therapeutic target in breast cancer, has been also proposed to drive invasion in LFs58, suggesting again similarities with metastatic ADC, and further suggesting repurposing a-HER-2 agents for the treatment of IPF. This evidence concerns the gene ERBB2 and breast cancer.